Topics:
Gynecologic Cancers • Medical Oncology • Immune-related adverse events • Rheumatology • Dermatology • Gynecologic Oncology • Multispecialty Spotlight
Can you continue checkpoint inhibitor therapy in the setting of severe cutaneous irAE while concurrently treating the cutaneous reaction?
Answer from: Medical Oncologist at Community Practice
Cutaneous reactions from immune checkpoint inhibitors (ICPi) generally fit into 3 categories: rash/inflammatory dermatitis, bullous dermatoses, and severe cutaneous adverse reaction (SCAR). For grade 1-2 rash/inflammatory dermatitis, if symptoms can be managed with topical therapy or non-steroidal o...
Sign in or Register to read more
Answer from: at Academic Institution
Yes, there is more data to be had. We do not know the right answers for this. There are some fundamental guidelines,Cancer side effects are defined by grades 1-4. Grades 3-4 often immunotherapy is held and possibly rechallenge - more data is needed. At the moment use your team of experts and each pa...